trending Market Intelligence /marketintelligence/en/news-insights/trending/rIePglceRI_ArJ7pXHwHeg2 content esgSubNav
In This List

ANI Pharmaceuticals buys US rights to 4 AstraZeneca drugs for $46.5M

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


ANI Pharmaceuticals buys US rights to 4 AstraZeneca drugs for $46.5M

ANI Pharmaceuticals, Inc. said it purchased U.S. rights to four of AstraZeneca PLC's drugs for $46.5 million.

The drugs include hypertension treatments Atacand and Atacand HCT, breast cancer medicine Arimidex, and Casodex for prostate cancer.

AstraZeneca, the U.K.'s second-biggest drugmaker, will continue to market and supply these four drugs outside the U.S. The British drugmaker has been selling off older assets as it focuses on developing new products.

The payment of $46.5 million would be in cash, royalties and sales-based milestones. ANI funded the acquisitions through a combination of cash and debt.

According to market intelligence firm IMS Health, these products generated about $19 million in U.S. sales during the trailing 12 months through October 2017.

ANI, based in Baudette, Minn., sells both branded and generic prescription drugs.